Egger, Matthias

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 467

Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap

Daneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 257

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Hoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 152

Let’s talk about sex characteristics—as a risk factor for invasive fungal diseases.

Egger, M., Hoenigl, M., Thompson, G. R., Carvalho, A., & Jenks, J. D. (2022) · Mycoses

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 82

Race and ethnicity: Risk factors for fungal infections?

Jenks, J. D., Aneke, C. I., Al-Obaidi, M. M., Egger, M., Garcia, L., Gaines, T., Hoenigl, M., & Thompson, G. R. (2023) · PLOS Pathogens

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 55

Metagenomic Next-Generation Sequencing of Plasma for Diagnosis of COVID-19-Associated Pulmonary Aspergillosis

Hoenigl, M., Egger, M., Price, J., Krause, R., Prattes, J., & White, P. L. (2023) · Journal of Clinical Microbiology

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 51